Side-by-side · Research reference
P21vsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BPhase 3HUMAN-REVIEWED14/43 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
P21
Sermorelin
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pituitary GHRH receptorWalker 1994
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
—
Yes — short pulse preserves feedback
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Sermorelin
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
Not specified
8–12 weeks per cycle
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
Once daily, pre-sleep
Lower / starter dose
—
100 mcg per dose
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep, fasted preferred
04Side Effects & Safety
Parameter
P21
Sermorelin
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Injection site reaction
—
Mild erythema, transient pain
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Glucose handling
—
Generally neutral
Absolute Contraindications
P21
- ·Use in humans not validated
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
P21
Sermorelin
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
SQ — abdomen or thigh. Rotate sites.
3. Timing
—
Pre-sleep, fasted.
4. Storage
—
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
P21
— no documented stacks
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition